Clinical Trials

List clinical trials by disease

The results of your search are listed below. To view the details of a trial or study, click on the "see details >" link. Or start a new search.

Searched for: Myelodysplastic Syndromes (MDS). 29 results shown below.

Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients

[Complete title: Feasibility and Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) Compared to Conventional Therapy for Older and Medically Infirm Patients Diagnosed with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes: A Prospective Observational Study]
Principal Investigator: Mohamed Sorror, MD, MSc
Study Number: 2368.00
Phase: NA

Donor Umbilical Cord Blood Transplant With or Without Ex-Vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes

[Complete title: Multi-Center, Open-Label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation with or without Infusion of Off–the-Shelf Ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients with Hematologic Malignancies]
Principal Investigator: Filippo Milano
Study Number: 2603.00
Phase: II

Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant (ICT-HCT)

[Complete title: Initial Cytoreductive Therapy for Myelodysplastic Syndrome prior to Allogeneic Hematopoietic Cell Transplantation (the ICT-HCT Study)]
Principal Investigator: Bart Scott, MD
Study Number: 2661.00
Phase: II

Abatacept as GVHD Prophylaxis Phase 2

[Complete title: Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis: A Randomized Controlled Trial]
Principal Investigator: Leslie Kean
Study Number: 2692.00
Phase: II

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

[Complete title: A Phase 1/2 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)]
Principal Investigator: Roland Walter, MD
Study Number: 2734.00
Phase: I/II

Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

[Complete title: Feasibility of Outpatient Induction Chemotherapy for Adult Patients with Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 7910
Phase: Pilot

JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

[Complete title: JAK-2 Inhibitor Prior to Allogeneic Stem Cell Transplant for Patients with Primary and Secondary Myelofibrosis: A Prospective Study]
Principal Investigator: Rachel Salit
Study Number: 9033
Phase: II

Allo vs. Hypomethylating/Best Supportive Care in MDS

[Complete title: A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome]
Principal Investigator: Bart Scott, MD
Study Number: 9129
Phase: III

Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myelodysplastic Syndrome or Acute Myeloid Leukemia

[Complete title: A Feasibility Study of “Early” Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory AML]
Principal Investigator: Mary-Elizabeth Percival
Study Number: 9567
Phase: Pilot

Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease

[Complete title: Transplantation of Umbilical Cord Blood for Patients with Hematological Diseases with Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen]
Principal Investigator: Ann Dahlberg
Study Number: 2010.00
Phase: II

Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant

[Complete title: A Phase II Study to Assess Immunosuppression with Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) for Prevention of Acute GVHD after Non-Myeloablative HLA Class I or II Mismatched Donor Hematopoietic Cell Transplantation – A Multi-Center Trial]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2206.00
Phase: II

Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Donor Umbilical Cord Blood Transplant

[Complete title: Transplantation of Umbilical Cord Blood in Patients with Hematological Malignancies Using a Treosulfan Based Preparative Regimen]
Principal Investigator: Filippo Milano
Study Number: 2275.00
Phase: II

Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

[Complete title: Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients with Hematologic Malignancies using Related, HLA-Haploidentical Donors: A Phase II trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source]
Principal Investigator: Rachel Salit
Study Number: 2372.00
Phase: II

Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

[Complete title: A Study Evaluating Escalating Doses of 90Y-DOTA-BC8 (anti-CD45) Antibody followed by Allogeneic Stem Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML) Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS)]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2468.00
Phase: I

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD

[Complete title: A Phase II Study Evaluating Selective Depletion of CD45RA+ T Cells from Allogeneic Peripheral Blood Stem Cell Grafts from HLA-Matched Related and Unrelated Donors for Prevention of GVHD]
Principal Investigator: Marie Bleakley, MD
Study Number: 2684.00
Phase: II

Telemonitoring Device in Managing Outpatient Care of Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia After Intensive Chemotherapy

[Complete title: Integrating a Telemonitoring Device into the Outpatient Management of Adult Patients Following Intensive Chemotherapy for MDS and Non-APL AML: A Randomized Pilot Study]
Principal Investigator: Anna Halpern
Study Number: 9105
Phase: Pilot

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy (RAFA)

[Complete title: A Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients with Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Risk-Adjusted Chemotherapy Only Cytoreduction with Busulfan, Cyclophosphamide and Fludarabine]
Principal Investigator: K.Scott Baker
Study Number: 9213
Phase: II

Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome

[Complete title: A Phase II Study of Deferasirox in Patients with Red Blood Cell Transfusion Dependent Myelodysplastic Syndromes]
Principal Investigator: Bart Scott, MD
Study Number: 9422
Phase: II

Filgrastim, Cladribine, Cytarabine and Mitoxantrone With Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

[Complete title: Addition of Sorafenib to G-CSF, Cladribine, Cytarabine and Mitoxantrone (G-CLAM) in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) Independent of FLT3-ITD status: A Phase 1/2 Study]
Principal Investigator: Anna Halpern
Study Number: 9510
Phase: I/II

Decitabine, Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

[Complete title: Randomized Phase 1 Study of Sequential (“Primed”) vs. Concurrent Decitabine in Combination with G-CSF, Cladribine, Cytarabine, and Mitoxantrone (G-CLAM) in Adults with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)]
Principal Investigator: Sarah Buckley
Study Number: 9713
Phase: I

Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

[Complete title: A Phase II Randomized, Placebo -Controlled, Multicenter Trial to Evaluate Protective Function of an Optimized Dose of CMVPepVax in Recipients of an Allogeneic Hematopoietic Stem Cell Transplant]
Principal Investigator: Joshua Hill
Study Number: 9733
Phase: II

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

[Complete title: Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome]
Principal Investigator: Todd Cooper
Study Number: AAML1531
Phase: III

An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies

[Complete title: Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects with Advanced Malignancies]
Principal Investigator: Ryan Cassaday
Study Number: 20152763
Phase: I

Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases

[Complete title: A Study Evaluating BPX-501 T cells and AP1903 for Prevention of GVHD after HLA-Haploidentical, Related, T Cell-Depleted Hematopoietic Cell Transplantation for Non-Malignant Diseases]
Principal Investigator: Ann Woolfrey, MD
Study Number: 2615.00
Phase: I/II

Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant

[Complete title: Phase 1/2 Study of CaspaCide T Cells from an HLA-Partially Matched Family Donor after Negative Selection of TCR aß+ T Cells in Pediatric Patients Affected by Hematological Disorders]
Principal Investigator: Ann Woolfrey, MD
Study Number: 9311
Phase: I/II

A Safety and Pharmacology Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

[Complete title: A Phase Ib Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered Alone or in Combination with Azacitidine in Patients with Myelodysplastic Syndromes]
Principal Investigator: Bart Scott, MD
Study Number: 9414
Phase: I

Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs

[Complete title: A Phase 3, Multicenter, Randomized, Open-label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents]
Principal Investigator: Bart Scott, MD
Study Number: 9723
Phase: III

Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA (INSPIRE)

[Complete title: A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician's Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent]
Principal Investigator: Bart Scott, MD
Study Number: 9782
Phase: III

Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome

[Complete title: A Phase 1 and Dose Expansion Cohort Study of Panobinostat in Combination with Fludarabine and Cytarabine in Pediatric Patients with Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplatic Syndrome.]
Principal Investigator: Todd Cooper
Study Number: SC-2029
Phase: I

Select a disease from the list below:

Limit results to studies enrolling:

OR

Search by Keyword, Investigator Name or Study ID#:

Limit results to studies enrolling:

OR

View all studies

Limit results to studies enrolling:

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials